Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
Gameto has created a three-part platform for ovarian therapeutics that will address menopause and assisted fertility.
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.
Amicus announced that it is halting its CLN6 Batten disease gene therapy program after studies failed to achieve consistent results.
Gene editing has broken through to a new level as a Maryland man recovers from surgery in which a heart from a genetically modified pig may save his life.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.